[Form 4] MacroGenics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Thomas Spitznagel, Sr. VP Technical Ops at MacroGenics, Inc. (MGNX), acquired 30,000 shares of common stock through the exercise of employee stock options on 08/15/2025. The options had an exercise price of $1.58 and convert to 30,000 shares upon exercise. After the reported transaction, 30,000 shares are beneficially owned directly. The option grant vests 25% one year after the grant date with the remaining 75% vesting in 12 substantially equal quarterly installments thereafter. The Form 4 was signed by an attorney-in-fact on 08/19/2025.

Positive

• Insider increased direct ownership by acquiring 30,000 shares via option exercise
• Standard vesting schedule disclosed, indicating retention-focused compensation (25% after one year, remaining 75% in 12 quarterly installments)

Negative

• No information provided on total outstanding shares or ownership percentage, so material impact cannot be quantified
• No sale disclosed to show diversification or liquidity choices by the reporting person

Insights

Corporate Governance Expert

TL;DR: Insider exercised 30,000 options at $1.58, creating direct ownership; routine corporate compensation activity with limited immediate market impact.

The filing documents a standard exercise of employee stock options by a senior officer, resulting in 30,000 shares held directly. The stated vesting schedule (25% after one year, then 12 quarterly installments for the remainder) aligns with common long-term incentive design intended to retain executives. There is no disclosure of sale or disposition of the shares, no change in percentage ownership disclosed, and no indication of unusual acceleration or related-party arrangements. From a governance perspective this is routine and does not, by itself, indicate material change to control or strategy.

Securities Analyst

TL;DR: Acquisition of 30,000 shares via option exercise is modest in scale and likely neutral for investors absent additional context.

The exercise price of $1.58 is explicitly stated and the conversion produced 30,000 common shares. Because the filing shows acquisition without subsequent sale, it signals insider ownership increase but provides no evidence of material vote or liquidity events. The transaction code indicates an acquisition (A). Without information on total outstanding shares or post-transaction ownership percentage, the investor impact cannot be quantified from this Form 4 alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Spitznagel Thomas

(Last) (First) (Middle)

9704 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr VP, Technical Ops

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.58	08/15/2025		A		30,000		(1)	08/15/2035	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. 25% of the options will vest and became exercisable one year after the grant date and the remaining 75% will vest in 12 substantially equal quarterly installments thereafter.

Remarks:

	/s/ Beth A. Smith, Attorney-in-fact	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Thomas Spitznagel report on Form 4 for MGNX?

He reported the acquisition through exercise of an employee stock option for 30,000 shares on 08/15/2025.

What was the exercise price for the options exercised by the MGNX executive?

The conversion or exercise price is stated as $1.58 per share.

How many shares does the reporting person beneficially own after the reported transaction?

The Form 4 shows 30,000 shares beneficially owned directly following the transaction.

What vesting terms are disclosed for the exercised options?

The filing states 25% vests one year after grant and the remaining 75% vests in 12 substantially equal quarterly installments.

When was the Form 4 signed and by whom?

The Form 4 was signed by an attorney-in-fact, Beth A. Smith, on 08/19/2025.